ONDINE BIOMEDICAL INC.
("Ondine Biomedical",
"Ondine" or the "Company")
Steriwave deploying in eight
new sites
Ondine Biomedical Inc. (LON:OBI), the Canadian life
sciences company pioneering light-activated antimicrobial
treatments to prevent and treat healthcare-associated infections
(HAIs), has made significant commercial progress to date in 2024,
ahead of management's expectations. Ondine's Steriwave® technology
is deploying in eight new healthcare facilities, including six new
hospitals. This brings the total number of hospitals to 22,
representing a 38% increase year-to-date and nearly quadruple the
number a year ago. Two orthopedic surgeon group practices in the
Toronto area will also shortly begin offering Steriwave to patients
undergoing elective orthopedic procedures.
In addition, The Ottawa Hospital (TOH) has confirmed
it is significantly expanding its use of Steriwave, building upon
the success of its pilot and a comprehensive cost-benefit
assessment within spine surgeries. This expansion means that
Steriwave will now be used across an additional site, and also
extends its application from spinal surgeries to also include TOH's
orthopedic and vascular surgery patients. Annually, Steriwave will
now be used prior to approximately 2,600 surgical procedures at
TOH, a threefold increase from the Steriwave pilot.
Discussions are ongoing with medical device
distributors to further expand the commercial reach of
Steriwave.
Driving this increase in hospital deployments is the
growing need to reduce avoidable hospital costs in an era of rising
antibiotic resistance. Recently published
findings reported a net saving approaching C$2,600 per spine
surgery patient treated with Steriwave nasal photodisinfection and
chlorhexidine skin decolonization.[1] Despite case complexity increasing
over the study period, the post-surgical infection rate dropped by
67%, resulting in estimated annual cumulative institutional savings
of $2.49 attributable to the use of the bundled protocol with
Steriwave.
The new commercial deployments of Steriwave described
above beyond the TOH expansion are paid adoptions that have begun
or were agreed before the end of February 2024:
· The first
three hospitals in Spain, including the Hospital Universitario La
Paz (HULP) in Madrid for a paid pilot of patients undergoing
elective orthopedic procedures. As anticipated by a previous
announcement, these are the first sign-ups through our distribution
partner in Spain.
· Sturgeon
Community Hospital, Alberta, (Alberta Health Services (AHS),
Canada's largest integrated health system). Sturgeon Community
Hospital is the third AHS hospital to deploy Steriwave. Steriwave
has been deployed for the reduction of surgical site infections
(SSIs) for patients undergoing breast reconstruction surgeries and
elective orthopedic procedures.
· Nanaimo
Regional General Hospital, British Columbia, (Island Health
Authority) has deployed Steriwave to reduce HAIs in patients
undergoing hip and knee surgeries.
· Two
orthopedic surgeon group practices in the Toronto area will also
begin offering Steriwave on a patient-pay basis to patients
undergoing elective orthopedic procedures. These groups operate
from Toronto Western Hospital, St Mary's General Hospital, and
Grand River Hospital all of which are in the Greater Toronto region
in Ontario, Canada.
Results presented at the the prestigious SPIE Photonics West
conference on 30 January 2024 in San Francisco, California
showed that treatment with Ondine's Steriwave® Nasal
Photodisinfection System significantly reduces pathogens in the
nose without long-term adverse effects on the nasal microbiome.
This is an important finding to allay potential concerns as to a
possible side-effect of Steriwave treatment, which has been used in
over 150,000 patients with no serious adverse events reported.
**ENDS**
Enquiries:
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences
company and leader innovating light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark
in Europe and the UK and is approved in Canada and several other
countries under the name Steriwave®. In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the FDA and is currently undergoing clinical trials for
regulatory approval. Products beyond nasal photodisinfection
include therapies for a variety of medical indications such as
chronic sinusitis, ventilator-associated pneumonia, burns, and many
other indications.
About
Steriwave®
Ondine's Steriwave® nasal photodisinfection system is
a patented technology using a proprietary light-activated
antimicrobial (photosensitizer) to destroy bacteria, viruses, and
fungi colonizing the nose. The photodisinfection treatment is
carried out by a trained healthcare professional and is an easy to
use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the
area with a specific wavelength of red laser light for less than
five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens without
causing long-term adverse effects on the nasal microbiome. A key
benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81%[2]-is that pathogens do not develop
resistance to the therapy.
Nasal decolonization is recommended in the 2016 WHO
Global guidelines for the prevention of surgical site
infections,[3] and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023,
recommend nasal decolonization for major surgical
procedures.[4]